机译:临床监测:英夫利昔单抗生物仿制性CT-P13治疗克罗恩病和溃疡性结肠炎
Charles Univ Prague Fac Med 2 Dept Internal Med V Uvalu 84 Prague Czech Republic;
Charles Univ Prague Fac Med 2 Dept Internal Med V Uvalu 84 Prague Czech Republic;
Charles Univ Prague Fac Med 3 Dept Internal Med 2 FNKV Prague Czech Republic;
Charles Univ Prague Fac Med 3 Dept Internal Med 2 FNKV Prague Czech Republic;
Inst Clin &
Expt Med Dept Hepatogastroenterol Prague Czech Republic;
Inst Clin &
Expt Med Dept Hepatogastroenterol Prague Czech Republic;
Inst Clin &
Expt Med Dept Hepatogastroenterol Prague Czech Republic;
Univ Hosp Ostrava Clin Internal Med Ostrava Czech Republic;
Univ Hosp Ostrava Clin Internal Med Ostrava Czech Republic;
Univ Hosp Olomouc Dept Internal Med 2 Olomouc Czech Republic;
Vitkovice Hosp Digest Dis Ctr Ostrava Czech Republic;
Univ Hosp Hradec Kralove Dept Internal Med Gastroenterol 2 Hradec Kralove Czech Republic;
Hosp Na Bulovce Dept Internal Med Prague Czech Republic;
Univ Hosp Plzen Bory Dept Internal Med 2 Plzen Czech Republic;
Univ Hosp Plzen Bory Dept Internal Med 2 Plzen Czech Republic;
Charles Univ Prague Fac Med 1 Gen Univ Hosp Prague Dept Internal Med 4 Clin Gastroenterol &
Charles Univ Prague Fac Med 1 Gen Univ Hosp Prague Dept Internal Med 4 Clin Gastroenterol &
Univ Econ Dept Econ &
Social Policy Prague Czech Republic;
Inst Clin &
Expt Med Dept Hepatogastroenterol Prague Czech Republic;
Biosimilar; CT-P13; inflammatory bowel disease; infliximab;
机译:临床监测:英夫利昔单抗生物仿制性CT-P13治疗克罗恩病和溃疡性结肠炎
机译:新型英夫利昔单抗生物仿制药CT-P13诱导疗法在克罗恩病和溃疡性结肠炎中的功效-单一中心的经验
机译:英夫利昔单抗BioSimilar CT-P13疗法在维持溃疡性结肠炎中的内窥镜缓解方面是有效的 - 多中心观察队列的结果
机译:分析综合性炎症性肠病小鼠模型以评估其疾病驱动途径以及与克罗恩病和溃疡性结肠炎的相关性
机译:生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者:加拿大分析
机译:临床监测:英夫利昔单抗生物仿制药CT-P13治疗克罗恩病和溃疡性结肠炎
机译:DOP062 BioSimilar Flowiximab(CT-P13)不逊于发起者Infliximab:来自Nor-Switch试验的Crohn病和溃疡性结肠炎的探索性IBD亚组分析